Gerresheimer Logo
DE000A0LD6E6
A0LD6E
GXI.DE

Gerresheimer

Loading quotes...

Forecast

There is no analyst data available for this company.


  • Gerresheimer makes progress on balance sheet and debt reduction, operations still mixed

    Gerresheimer has cleared balance-sheet issues tied to the delayed report and plans to sell Centor and Primary Packaging Plastics, which should significantly reduce debt. Operationally the first quarter remained weak: revenue around €524 million, adjusted EBITDA fell from €81 million to €66 million. Free cash flow improved markedly to -€32 million versus -€141 million a year earlier. Management expects a pickup in business momentum in the second half, which could further ease the metrics. » More on finanzen.net


  • Gerresheimer: adjusted EBITDA falls 19% – shares rise 2.8% after cash‑flow improvement

    Gerresheimer reports adjusted EBITDA of €66m for Q1 2026 (-19%) and a margin of 12.6% (previous year 15.7%), on slightly higher revenue of €524m. Free cash flow improved significantly to -€32m from -€141m, driven by active inventory reduction and throttled production volumes, which weigh on profitability in the short term. The Containment & Delivery Systems segment performed positively with a higher margin due to strong demand and new U.S. production ramp‑ups. The quarterly release was delayed due to internal reviews of revenue recognition, the company still lacks a permanent CEO, and management is aiming for a turnaround in the second half. » More on de.investing.com


  • Gerresheimer rises sharply after improved free cash flow and optimistic H2 forecast

    The Gerresheimer share climbed about 5.7% to €26.68 after the company published preliminary Q1 figures showing a marked improvement in free cash flow. Revenue rose slightly to €524m, but adjusted EBITDA fell from €81m to €66m and the margin dropped to 12.6% due to a strategic realignment in favor of cash generation. Investors were also reassured by a more optimistic expectation for the second half of the year despite the recent CEO change to interim co‑leadership. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics
In 2025, Gerresheimer has already paid +0,04 in dividends. The last payout was in June 2025.

Financials

In the last quarter, Gerresheimer had revenue of +639.49m and net profit of 306.63m
(EUR) Nov 2025
YoY
Revenue +639.49m -
Gross profit +1.78m -
Net profit 306.63m -
EBITDA +35.02m -

Fundamentals

Metric Value
Market capitalization
+886.99m
Number of shares
34.54m
52-week high/low
+45,24 - +14,83
Dividends No
Beta
0,47
P/E ratio
2,77
PEG ratio
+0,01
P/B ratio
+0,82
P/S ratio
+0,38

Company profile

Die Gerresheimer AG produziert und vertreibt zusammen mit ihren Tochtergesellschaften weltweit Verpackungsprodukte sowie Geräte und Lösungen zur Verabreichung von Medikamenten. Das Unternehmen ist in den Geschäftsbereichen Plastics & Devices, Primary Packaging Glass und Advanced Technologies tätig. Der Geschäftsbereich Plastics & Devices bietet Systeme zur Verabreichung von Medikamenten an, darunter Inhalatoren, Insulin-Pen-Systeme, vorfüllbare Spritzen und Diagnosesysteme für die Pharma-, Biotech-, Diagnostik- und Medizintechnikindustrie; Behälter und Verschlüsse, PET-Flaschen, Augentropfer, Nasensprays, Vernebler, Applikatoren und Zubehör für feste, flüssige und ophthalmische Anwendungen sowie Flaschen und Behälter für Nahrungsergänzungsmittel. Der Geschäftsbereich Primary Packaging Glass bietet Primärverpackungen aus Glas für die Pharma- und Kosmetikindustrie an, z. B. Infusions-, Tropfflaschen und Sirupflaschen, Injektionsfläschchen, Ampullen und Karpulen, Miniaturflaschen und Glasbehälter für flüssige Lebensmittel, Gewürze und Spirituosen sowie Verpackungslösungen für Parfüms, Deodorants, Hautpflege- und Wellnessprodukte sowie Beauty- und Pharmaprodukte. Der Geschäftsbereich Advanced Technologies entwickelt für Kunden aus der Pharma- und Biotech-Branche intelligente Verabreichungssysteme für Medikamente, wie z. B. Mikropumpen, die zur Selbstverabreichung von Medikamenten gegen die Parkinson-Krankheit oder Herzinsuffizienz eingesetzt werden. Das Unternehmen wurde 1864 gegründet und hat seinen Hauptsitz in Düsseldorf, Deutschland.

Name
Gerresheimer
CEO
Uwe Ferdinand Röhrhoff
Headquarters Düsseldorf, nw
Germany
Website
Sector
Health Care
Industry
Health Care Technology
IPO
06/11/2007
Employees 13.528

Ticker symbols

Exchange Symbol
XETRA
GXI.DE
Pnk
GRRMF
SIX
GXI.SW
Frankfurt
GXI.F
Düsseldorf
GXI.DU
Hamburg
GXI.HM
London
0NTI.L
München
GXI.MU
Wien
GXI.VI

Discover assets

Shareholders of Gerresheimer also invest in the following assets

🍪

Parqet  uses cookies. Learn more